Transcode Therapeutics, Inc. (RNAZ) stock
RNAZNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.34−0.06 (-4.61%)
Close on Nov 18, 2026Market cap $1.36MP/E –Yield –
Transcode Therapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Transcode Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$45.13M. For fiscal 2025 it was -$27.98M. The highest annual figure on record is -$726.60K in fiscal 2020.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$27.98M | – |
| FY2024 | Dec 31, 2024 | -$15.66M | – |
| FY2023 | Dec 31, 2023 | -$19.42M | – |
| FY2022 | Dec 31, 2022 | -$18.63M | – |
| FY2021 | Dec 31, 2021 | -$6.15M | – |
| FY2020 | Dec 31, 2020 | -$726.60K | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$6.79M | – |
| Q1 FY2026 | Mar 31, 2026 | -$17.76M | – |
| Q4 FY2025 | Dec 31, 2025 | -$16.03M | – |
| Q3 FY2025 | Sep 30, 2025 | -$4.56M | – |
| Q2 FY2025 | Jun 30, 2025 | -$4.22M | – |
| Q1 FY2025 | Mar 31, 2025 | -$3.17M | – |
| Q4 FY2024 | Dec 31, 2024 | -$5.09M | – |
| Q3 FY2024 | Sep 30, 2024 | -$2.17M | – |
| Q2 FY2024 | Jun 30, 2024 | -$5.11M | – |
| Q1 FY2024 | Mar 31, 2024 | -$3.29M | – |
| Q4 FY2023 | Dec 31, 2023 | -$4.10M | – |
| Q3 FY2023 | Sep 30, 2023 | -$5.31M | – |
| Q2 FY2023 | Jun 30, 2023 | -$5.12M | – |
| Q1 FY2023 | Mar 31, 2023 | -$4.89M | – |
| Q4 FY2022 | Dec 31, 2022 | -$5.50M | – |
| Q3 FY2022 | Sep 30, 2022 | -$4.95M | – |
| Q2 FY2022 | Jun 30, 2022 | -$4.71M | – |
| Q1 FY2022 | Mar 31, 2022 | -$3.48M | – |
| Q4 FY2021 | Dec 31, 2021 | -$2.99M | – |
| Q3 FY2021 | Sep 30, 2021 | -$2.36M | – |
| Q2 FY2021 | Jun 30, 2021 | -$355.53K | – |
| Q1 FY2021 | Mar 31, 2021 | -$449.47K | – |
| Q4 FY2020 | Dec 31, 2020 | -$379.00K | – |
| Q3 FY2020 | Sep 30, 2020 | -$239.49K | – |
| Q2 FY2020 | Jun 30, 2020 | -$91.61K | – |
See a number that looks wrong?